Purple Biotech Stock Performance
| PPBT Stock | USD 2.98 0.13 4.56% |
The company holds a Beta of -0.0834, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Purple Biotech are expected to decrease at a much lower rate. During the bear market, Purple Biotech is likely to outperform the market. At this point, Purple Biotech has a negative expected return of -1.09%. Please make sure to check Purple Biotech's potential upside, as well as the relationship between the kurtosis and day typical price , to decide if Purple Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Purple Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 4.56 | Five Day Return 3.47 | Year To Date Return (35.08) | Ten Year Return (99.53) | All Time Return (99.53) |
Last Split Factor 1:20 | Dividend Date 2020-08-21 | Last Split Date 2024-09-17 |
1 | Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second ... | 12/02/2024 |
2 | Purple Biotech Announces 2.8 Million Registered Direct Offering of American Depositary Shares | 12/03/2024 |
3 | Purple Biotech Announces Closing of 2.8 Million Registered Direct Offering of American Depositary Shares | 12/05/2024 |
4 | Purple Biotech Expands ATM Offering by 1.33 Million - MSN | 01/08/2025 |
5 | Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial | 02/18/2025 |
| Begin Period Cash Flow | 15 M |
Purple |
Purple Biotech Relative Risk vs. Return Landscape
If you would invest 657.00 in Purple Biotech on December 3, 2024 and sell it today you would lose (359.00) from holding Purple Biotech or give up 54.64% of portfolio value over 90 days. Purple Biotech is currently does not generate positive expected returns and assumes 6.4546% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Purple, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Purple Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Purple Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Purple Biotech, and traders can use it to determine the average amount a Purple Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1693
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PPBT |
Estimated Market Risk
| 6.45 actual daily | 57 57% of assets are less volatile |
Expected Return
| -1.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.17 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Purple Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Purple Biotech by adding Purple Biotech to a well-diversified portfolio.
Purple Biotech Fundamentals Growth
Purple Stock prices reflect investors' perceptions of the future prospects and financial health of Purple Biotech, and Purple Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Purple Stock performance.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 1.72 M | ||||
| Shares Outstanding | 2.58 M | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 58.08 X | ||||
| Gross Profit | (196 K) | ||||
| EBITDA | (22.23 M) | ||||
| Net Income | (19.88 M) | ||||
| Cash And Equivalents | 36.02 M | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 351 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.94 X | ||||
| Book Value Per Share | 16.98 X | ||||
| Cash Flow From Operations | (19.23 M) | ||||
| Earnings Per Share | (8.10) X | ||||
| Market Capitalization | 7.7 M | ||||
| Total Asset | 44.3 M | ||||
| Retained Earnings | (137.45 M) | ||||
| Working Capital | 8.61 M | ||||
About Purple Biotech Performance
Assessing Purple Biotech's fundamental ratios provides investors with valuable insights into Purple Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Purple Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -6.1 M | -6.4 M | |
| Return On Capital Employed | 0.54 | 0.57 |
Things to note about Purple Biotech performance evaluation
Checking the ongoing alerts about Purple Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Purple Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Purple Biotech generated a negative expected return over the last 90 days | |
| Purple Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (19.88 M) with loss before overhead, payroll, taxes, and interest of (196 K). | |
| Purple Biotech currently holds about 36.02 M in cash with (19.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.0. | |
| Purple Biotech has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial |
- Analyzing Purple Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Purple Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Purple Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Purple Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Purple Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Purple Biotech's stock. These opinions can provide insight into Purple Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.